会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • SPLITTING GP41
    • 分割GP41
    • WO2010089402A1
    • 2010-08-12
    • PCT/EP2010051524
    • 2010-02-08
    • MYMETICS CORPFLEURY SYLVAINBOMSEL MORGANE
    • FLEURY SYLVAINBOMSEL MORGANE
    • A61K39/21C07K14/16
    • C07K14/005A61K39/12A61K39/21A61K2039/5258A61K2039/54A61K2039/543A61K2039/545A61K2039/55555A61K2039/575A61K2039/6018C07K2319/40C12N2740/15022C12N2740/16122C12N2740/16134C12N2760/16142
    • The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising : a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.
    • 本发明涉及HIV的治疗或预防性治疗方法,特别是一种预防性疫苗方法,其至少包括:向患者施用包含gp41的膜近端胞外域(MPER)的广泛中和表位的第一抗原, 并且向相同的患者施用包含修饰的多肽的第二抗原,其包含由式NLC表示的三个连续区段N,L和C,并且包含:gp41(N)的N-螺旋区域,gp41的C-螺旋区域(C )和包含在N和C-螺旋之间的合成接头(L)的连接环,所述接头代替gp41的氨基酸593-617,编号方案基于原型分离物HIV-1 HxB2进化枝B菌株,所述 所述多肽包含与小白细胞介素2具有最小免疫原性交叉反应性的所述多肽,所述多肽包含所述犊牛素-1中和和98.6D表位,而不是2F5和4E10表位,而不是融合肽。